Viewing Study NCT06590857

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:59 PM
Ignite Modification Date: 2026-02-20 @ 3:44 PM
Study NCT ID: NCT06590857
Status: RECRUITING
Last Update Posted: 2025-08-12
First Post: 2024-09-03
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Sponsor: RayzeBio, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Breast Cancer View
None HER2-negative Breast Cancer View
None ER+ Breast Cancer View
None Advanced Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Actinium View
None Alpha-Emitter View
None SSTR+ MBC View
None ER+, HER2-, MBC View
None RYZ101 View
None 225Ac View
None Targeted Radiotherapy View
None Radiopharmaceutical View
None SSTR+ ABC View
None ER+, HER2-, ABC View